Celcuity, Inc. (CELC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put CELC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Improve earnings to positive by FY 2027: EPS -1.1% vs 0.7% target.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 40%, softest on returns on capital.
View QualityThis stock is volatile — it swings about 2% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskCelcuity's growth depends on shipping REVTORPYK in late Q3 2026. This launch is crucial to justify its current price. Revenue generation is expected to start in late Q3 2026. The last quarter saw a beat with an EPS of -1.07. The stock trades at a low confidence valuation, with no clear multiple. Peer multiples imply a price about 42% above where it trades. Risks include potential delays in REVTORPYK shipments due to regulatory issues. This read is provisional.
Trailing returns as of 2026-09-04. CELC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering CELC (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for CELC in the last 4 months.
Continue this research
Compare CELC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CELC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CELC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Submit sNDA for gedatolisib in PIK3CA mutant cohort in Q3 2026
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $95.70
The last 12 months of price, then the range of analyst 12-month targets from today’s $95.70.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
sNDA submission aligns with management's timeline.

Threatens: Finance operations through 2027 with cash and debt
Convertible note offering may dilute shareholder value.
Threatens: Finance operations through 2027 with cash and debt
Convertible notes could impact financing operations.
Threatens: Launch gedatolisib commercially in Q3 2026
Stock drop despite positive results raises concerns.
Advances: Launch gedatolisib commercially in Q3 2026
FDA decision is critical for gedatolisib launch.
Advances: Launch gedatolisib commercially in Q3 2026
Expansion of trial design supports product development.